Cardiac medication during pregnancy, data from the ROPAC.

Area of Science:

• Cardiology
• Maternal-Fetal Medicine
• Pharmacology

Background:

• Limited data exists on the pharmacological management of pregnant women with cardiovascular disease.
• Understanding medication use and fetal outcomes is crucial for this high-risk population.

Purpose of the Study:

• To describe the types and frequency of cardiac medications used during pregnancy in women with cardiovascular disease.
• To assess the association between cardiac medication use and fetal outcomes.

Main Methods:

• A multinational study involving 1321 pregnant women with structural heart disease from 2007-2011.
• Data collected on medication use (beta-blockers, antiplatelet agents, diuretics, ACE inhibitors, statins) and fetal outcomes.
• Statistical analysis to compare outcomes between medication users and non-users, adjusting for confounding factors.

Main Results:

• 32% of pregnant women with heart disease used cardiac medication; beta-blockers were most common (22%).
• Medication use was associated with a 2.0-fold increased odds of adverse fetal events.
• Babies exposed to beta-blockers had significantly lower birth weight; ACE inhibitors were linked to the highest fetal malformation rate (8%).

Conclusions:

• Cardiac medication is frequently used in pregnant women with heart disease and is associated with increased adverse fetal events.
• Specific medications like beta-blockers and ACE inhibitors showed particular associations with negative fetal outcomes.
• Further randomized trials are necessary to elucidate the direct effects of these medications versus the underlying maternal cardiac conditions.